Last $0.12 USD
Change Today -0.0055 / -4.53%
Volume 212.3K
AEMD On Other Exchanges
Symbol
Exchange
OTC US
As of 3:58 PM 10/1/14 All times are local (Market data is delayed by at least 15 minutes).

aethlon medical inc (AEMD) Snapshot

Open
$0.12
Previous Close
$0.12
Day High
$0.12
Day Low
$0.12
52 Week High
03/12/14 - $0.27
52 Week Low
09/18/14 - $0.10
Market Cap
30.3M
Average Volume 10 Days
346.6K
EPS TTM
$-0.04
Shares Outstanding
261.1M
EX-Date
--
P/E TM
--
Dividend
--
Dividend Yield
--
Current Stock Chart for AETHLON MEDICAL INC (AEMD)

Related News

No related news articles were found.

aethlon medical inc (AEMD) Related Businessweek News

No Related Businessweek News Found

aethlon medical inc (AEMD) Details

Aethlon Medical, Inc., a medical device company, focuses on creating devices for the treatment of cancer, infectious diseases, and other life-threatening conditions. It develops Aethlon Hemopurifier, a medical device that targets the elimination of circulating viruses and tumor-secreted exosomes that promote cancer progression. The company’s Aethlon Hemopurifier is intended for the treatment of antiviral drug-resistance in hepatitis-C virus and human immunodeficiency virus infected individuals; serves as a countermeasure against viral pathogens not addressed by drug or vaccine therapies; and represents the therapeutic strategy to address cancer promoting exosomes. It also develops exosome-based products to diagnose and monitor cancer, infectious diseases, and neurological disorders; and is developing a medical device to reduce the incidence of sepsis in combat-injured soldiers. The company was founded in 1991 and is based in San Diego, California.

10 Employees
Last Reported Date: 07/15/14
Founded in 1991

aethlon medical inc (AEMD) Top Compensated Officers

Founder, Chairman, Chief Executive Officer, P...
Total Annual Compensation: $400.0K
President and Director
Total Annual Compensation: $240.0K
Chief Financial Officer and Senior Vice Presi...
Total Annual Compensation: $183.0K
Chief Scientific Officer, Vice President and ...
Total Annual Compensation: $195.0K
Compensation as of Fiscal Year 2014.

aethlon medical inc (AEMD) Key Developments

Aethlon Medical Announces Dengue Virus Treatment Agreement with Qualtran, LLC; to Initiate the First FDA Approved Study of Hemopurifier(R) Therapy

Aethlon Medical, Inc. announced that it has entered into an agreement with Qualtran, LLC that would expand human clinical studies of Hemopurifier(R) therapy to include individuals infected with dengue virus, a global health threat, which is not addressed with approved drug or vaccine therapies. Aethlon is also in the process of initiating the first FDA approved study of Hemopurifier(R) therapy in individuals infected with hepatitis c virus (HCV). The Hemopurifier(R) is a first-in-class therapeutic device that targets the rapid elimination of circulating viruses and tumor-secreted exosomes that promote cancer progression. Aethlon disclosed that it will incorporate data from the proposed dengue treatment study into a Humanitarian Use Device (HUD) submission, which provides an alternative FDA pathway for obtaining market approval for medical devices that address disease conditions that affect fewer than 4,000 individuals in the U.S. per year. Dengue also represents a disease condition where efficacy treatment studies in the U.S. are not feasible. The treatment of dengue virus represents a significant unmet need and serious global health challenge.

Aethlon Medical Receives Notice of DARPA Contract Renewal

Aethlon Medical, Inc. announced that the Defense Advanced Research Projects Agency (DARPA) has informed the company that it plans to exercise an option to proceed with year four of a five-year $5.9 million contract that was awarded to Aethlon on September 30, 2011 under DARPA's Dialysis-Like Therapeutics (DLT) program. The fourth year of Aethlon's DLT contract contains three milestones representing a potential of $669,292 in revenue opportunity. To date, Aethlon has invoiced $4,252,037 to DARPA for achieving twenty of twenty-three milestone objectives targeted in the first three years of the DLT program. The fourth year of Aethlon's DLT contract contains three milestones representing a potential of $669,292 in revenue opportunity. To date, Aethlon has invoiced $4,252,037 to DARPA for achieving twenty of twenty-three milestone objectives targeted in the first three years of the DLT program. The goal of the Dialysis-Like Therapeutics (DLT) program is to develop a portable device that removes "dirty" blood from the body, separates harmful agents, and returns 'clean' blood to the body in a manner similar to dialysis treatment of kidney failure. The resulting device could decrease the morbidity and mortality of sepsis, thereby saving thousands of lives and billions of dollars in the United States annually.

Aethlon Medical, Inc. Announces Receipt of IRB Approval to Initiate Hemopurifier(R) Clinical Studies

Aethlon Medical, Inc. announced that it has received independent internal review board (IRB) approval to initiate human clinical studies of Hemopurifier(R) therapy at DaVita MedCenter Dialysis located in Houston, Texas. Aethlon previously disclosed that the United States Food and Drug Administration (FDA) had approved an Investigational Device Exemption (IDE) that would allow for the initiation of Hemopurifier(R) feasibility studies in the United States. As a result of the independent IRB approval, the Company is now permitted to initiate the IDE approved study. Enrollment of patients who meet the study inclusion/exclusion criteria is expected to begin in the coming weeks. The Hemopurifier(R) is therapeutic device that targets the rapid elimination of circulating viruses and tumor-secreted exosomes that suppress the immune system of cancer patients. Upon receipt of IDE approval from FDA, Aethlon initiated discussions with various clinical partner candidates. On February 26, 2014, the Company disclosed that it had reached an agreement in principle with DaVita Clinical Research(R) (DCR) and subsequently disclosed that it had completed a definitive agreement with DCR on May 20, 2014. DCR is a specialty contract research organization (CRO) with experience in conducting more than 300 early phase clinical trials. As a subsidiary of DaVita Healthcare Partners Inc, DCR has access to one third of the total U.S. ESRD patient population and maintains a network that exceeds 150 investigative physicians' practices at more than 250 clinical sites. Under the feasibility study protocol, Aethlon will enroll ten end-stage renal disease (ESRD) patients who are infected with the Hepatitis C virus (HCV) to demonstrate the safety of Hemopurifier(R) therapy in an infectious disease model. Upon successful completion of the feasibility study, Aethlon plans to conduct pivotal efficacy studies required for market clearance to treat HCV and other chronic viral indications. Previous clinical studies of Hemopurifier(R) therapy have been conducted in HIV and HCV-infected individuals at the Apollo Hospital, Fortis Hospital, Sigma New Life Hospital, and the Medanta Medicity Institute, all located in India. Aethlon's feasibility study will also contribute safety data to advance the Hemopurifier(R) as a broad-spectrum countermeasure against high-risk bioterror and pandemic threats, which are so lethal they do not allow for the administration of clinical efficacy studies. In this regard, the Company is pursuing Emergency Use Authorization (EUA) approvals based on previous human treatment outcomes and pre-clinical validations against a broad-spectrum of viral pathogens. Previously, in vitro studies of bioterror and pandemic threats have verified Hemopurifier(R) capture of ebola hemorrhagic virus, dengue hemorrhagic virus, lassa hemorrhagic virus, H5N1 avian influenza (bird flu), the reconstructed 1918 influenza virus (r1918), 2009 H1N1 influenza virus (swine flu), West Nile virus, and monkeypox, which serves as a model for human smallpox infection. These studies were conducted with leading government and non- government research organizations, including The U.S. Army Medical Research Institute of Infectious Diseases (USAMRIID), The Centers for Disease Control and Prevention (CDC), The National Institute of Virology (NIV), The Battelle Biomedical Research Center (BBRC) and The Southwest Foundation for Biomedical Research (SFBR). Aethlon also disclosed that it may pursue investigate Humanitarian Use Device (HUD) pathways for orphan indications that affect fewer than 4,000 individuals in the U.S. each year.

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
AEMD:US $0.12 USD -0.0055

AEMD Competitors

Market data is delayed at least 15 minutes.

Company Last Change
No competitor information is available for AEMD.
View Industry Companies
 

Industry Analysis

AEMD

Industry Average

Valuation AEMD Industry Range
Price/Earnings NM Not Meaningful
Price/Sales 18.7x
Price/Book NM Not Meaningful
Price/Cash Flow NM Not Meaningful
TEV/Sales 19.5x
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact AETHLON MEDICAL INC, please visit www.aethlonmedical.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.